Impact of obinutuzumab alone and in combination for follicular lymphoma
Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease...
Guardado en:
Autores principales: | Sarraf Yazdy M, Cheson BD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/259d4bf0f16349c4983cd5e49a0ed804 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat YF, et al.
Publicado: (2016) -
CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
por: Senem MARAL, et al.
Publicado: (2021) -
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Natali Pflug, et al.
Publicado: (2021) -
Plasmablastic lymphoma: current perspectives
por: Lopez A, et al.
Publicado: (2018) -
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
por: Farina F, et al.
Publicado: (2014)